106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2017 All rights reserved
Disclaimer
is pocket card is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines
do not account for individual variation among patients. is pocket card does not purport to
suggest any particular course of medical treatment. Use of the practice guidelines and this resource
are voluntary. e practice guidelines and additional information are available at www.asco.org/
guidelines/MetPC. Copyright © 2016 by American Society of Clinical Oncolog y.
All rights reserved.
ASCOMET17013
Abbreviations
ASCO, American Society of Clinical Oncolog y; CT, computerized tomography; ECOG,
Eastern Cooperative Oncolog y Group; GI, gastrointestinal; NAB, nanoparticle albumin-bound;
OS, overall survival; PS, performance status
Source
Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE,
Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru
D. Metastatic Pancreatic Cancer: American Society of Clinical Oncolog y Clinical Practice
Guideline. J Clin Oncol. 2016 Aug 10;34(23):2784-96.
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, patient
versions, frequently asked questions, and other clinical tools and resources, is available at
www.asco.org/guidelines/MetPC and www.asco.org/guidelineswiki
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength Of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
CB
Consensus-
based
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
Ins Insufficient
